Search

Displaying results 491 - 500 of 8415 in total
  1. Drug

    Trabectedin

    go.drugbank.com/drugs/DB05109
    ApprovedInvestigational

    It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. … Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer.

  2. Drug

    Vitamin D

    go.drugbank.com/drugs/DB11094
    ApprovedInvestigationalNutraceuticalVet approved

    Vitamin D ultimately comprises a group of lipid-soluble secosteroids responsible for a variety of biological effects, some of which include increasing the intestinal absorption of calcium, magnesium, and phosphate. With reference to huma...

    Mixtures: PMS-oscalvit, Children's Chew Multi & Min Tab
  3. Drug

    Diphenhydramine

    go.drugbank.com/drugs/DB01075
    ApprovedInvestigational

    As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the … However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties [L5269, F3352].

    Mixtures: Compresso Pap 80 DplProducts: PMS-diphenhydramine Elixir 2.5mg/ml, PMS-diphenhydramine Hydrochloride Inj 50mg/ml
  4. Drug

    Butriptyline

    go.drugbank.com/drugs/DB09016
    ApprovedWithdrawn

    Butriptyline is a tricyclic antidepressant which has been used in Europe since 1974. It is the isobutyl side chain homologue of amitriptyline.

  5. Drug

    Margetuximab

    go.drugbank.com/drugs/DB14967
    ApprovedInvestigational

    The HER2 oncoprotein, the product of the human _ERBB2_/mouse _neu_ genes, is a member of the HER family of receptor tyrosine kinases that includes the epidermal growth factor receptor (EGFR). … [A225751, A225756, A225766, A191829, L27986] Margetuximab binds to the same epitope on the HER2 extracellular domain and induces the same effects as [trastuzumab].

  6. Drug

    Vorapaxar

    go.drugbank.com/drugs/DB09030
    Approved

    of myocardial infarction (MI) or with peripheral arterial disease (PAD). … By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation.

    Categories: Receptor, PAR-1, antagonists & inhibitorsSynonyms: [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-Fluorophényl)-2-pyridinyl]vinyl}-1-méthyl-3-oxododécahydronaphto[2,3-c]furan-6-yl]carbamate d'éthyle, Carbamic acid, [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-fluorophenyl)-2- pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl ester
  7. Drug

    Azithromycin

    go.drugbank.com/drugs/DB00207
    ApprovedInvestigational

    It was initially approved by the FDA in 1991 [A174175]. … In March 2020, a small study was funded by the French government to investigate the treatment of COVID-19 with a combination of azithromycin and the anti-malaria drug [hydroxychloroquine].

    Products: PMS-azithromycin, Zithromax - Pws Orl 100mg/5ml
  8. Drug

    Dibenzepin

    go.drugbank.com/drugs/DB13225
    Approved

    Dibenzepin is approved for use in Europe.

  9. Drug

    Glimepiride

    go.drugbank.com/drugs/DB00222
    ApprovedInvestigational

    It is sometimes classified as a third-generation SU because it has larger substitutions than other second-generation SUs. … [A177703] Compared to other SUs, glimepiride was associated with a lower risk of developing hypoglycemia and weight gain in clinical trials [A177709] as well as fewer cardiovascular effects than other

    Products: PMS-glimepiride
  10. Drug

    Risankizumab

    go.drugbank.com/drugs/DB14762
    ApprovedInvestigational

    [L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019.